title: HIV-associated pulmonary arterial hypertension: from bedside to the future.
abstract: Pulmonary arterial hypertension (PAH) is a life-threatening complication of HIV infection. The prevalence of HIV-associated PAH (HIV-PAH) seems not to be changed over time, regardless of the introduction of highly active antiretroviral therapy (HAART). In comparison with the incidence of idiopathic PAH in the general population (1-2 per million), HIV-infected patients have a 2500-fold increased risk of developing PAH. HIV-PAH treatment is similar to that for all PAH conditions and includes lifestyle changes, general treatments and specific treatments.
authors.affiliation: Cardiology Department, University of Foggia, Foggia, Italy.
authors.forename: Michele
authors.initials: M
authors.lastname: Correale
authors.forename: Giuseppe Antonio
authors.initials: GA
authors.lastname: Palmiotti
authors.forename: Maria Maddalena
authors.initials: MM
authors.lastname: Lo Storto
authors.forename: Deodata
authors.initials: D
authors.lastname: Montrone
authors.forename: Maria Pia
authors.initials: MP
authors.lastname: Foschino Barbaro
authors.forename: Matteo
authors.initials: M
authors.lastname: Di Biase
authors.forename: Donato
authors.initials: D
authors.lastname: Lacedonia
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D006976:Hypertension, Pulmonary / Q000150:complications* / Q000188:drug therapy
chemical_list: D000959:Antihypertensive Agents
keywords: AIDS; HIV; pulmonary arterial hypertension; pulmonary hypertension